Inhibition of the immune checkpoints using monoclonal antibodies that block the T-cell molecules PD-1, PD-L1, as well as CTLA4 has emerged as a novel anti-cancer treatment with extraordinary survival advantages (Curran et al., 2010). Here, CD274 is linked to cancer.